drugset / Trial / NCT02452307
Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy
RandomizedParallel-groupOpen-labelTreatment
Summary
The study evaluates the prostate-specific antigen (PSA) response in HLA-A\*02 positive patients with biochemical recurrence after radical prostatectomy treated with a prostate-specific peptide vaccine in combination with different immune-adjuvants.
Timeline
- Start
- 2004-04
- Primary completion
- 2017-10
- Completion
- 2017-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) | Unknown | — | Intravenous |
| Subject | Imiquimod | Other / unclassified | — | Other |
| Subject | Peptide vaccine | Vaccine | — | Subcutaneous |
| Subject | Protamin | Unknown | — | Subcutaneous |
| Subject | mRNA | Messenger RNA (mRNA) | — | Subcutaneous |
| Background | incomplete Freund's adjuvant | Other / unclassified | — | Subcutaneous |